Revolution Medicines Inc.
Revolution Medicines Announces Major Equity Offering
Summary
Revolution Medicines, Inc. announced on April 14, 2026, an equity offering involving the sale of 10,563,381 shares of common stock at $142.00 per share, with an additional 1,584,506 shares sold under the underwriters' option. The offering is expected to close on April 16, 2026, and is part of a broader capital raise that also includes a convertible note offering of $500,000,000 aggregate principal amount of 0.50% Convertible Senior Notes due 2033, expected to close on April 17, 2026. The net proceeds from the equity offering are expected to be approximately $1,650.4 million after deducting underwriting discounts, commissions, and estimated offering expenses.
Profitelligence Alerts
Get alerts for RVMD
Be first to know when Revolution Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Revolution Medicines Inc.
Revolution Medicines Inc. is a biotechnology company primarily focused on the development of targeted therapies for cancer treatment. The company aims to create innovative drugs by leveraging the potential of inhibitors that target specific oncogenic pathways. Revolution Medicines Inc. specializes in synthetic lethal technologies and non-covalent inhibitors to address complex molecular targets found in cancer cells. With a strong emphasis on research and development, it collaborates with academic institutions and partners within the biopharmaceutical industry to advance its pipeline of drug candidates. Revolution Medicines Inc. is significantly involved in the oncology sector, with potential impacts on patient care through its commitment to developing precision medicines. As a key player in the biotech landscape, the company contributes to the ongoing evolution of cancer treatment methodologies, seeking to extend and improve patients' lives through state-of-the-art therapeutic options.
Official SEC Documents
Advertisement